Ascentage Pharma Group International (NASDAQ:AAPG) Trading Down 5.2% – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares fell 5.2% during trading on Monday . The company traded as low as $18.32 and last traded at $18.32. Approximately 573 shares were traded during trading, a decline of 92% from the average session volume of 6,970 shares. The stock had previously closed at $19.33.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AAPG. BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price for the company. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Stock Up 3.5%

The firm’s 50 day moving average is $18.56 and its 200-day moving average is $22.38. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57.

Institutional Investors Weigh In On Ascentage Pharma Group International

Hedge funds have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter valued at about $383,000. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. Finally, UBS Group AG increased its stake in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.